The remarkably robust dealmaking in the medtech sector last year seems to have led venture investors to rediscover their willingness to back young companies. Of all the venture cash invested in device and diagnostics makers so far this year, 11% went into seed and series A rounds – the highest proportion since 2017.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,